The European Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment

被引:103
作者
Haro, JM
Edgell, ET
Jones, PB
Alonso, J
Gavart, S
Gregor, KJ
Wright, P
Knapp, M
机构
[1] St Joan Deu SSM, Res & Dev Unit, Barcelona, Spain
[2] Eli Lilly & Co, European Hlth Outcomes Res, Surrey, England
[3] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
[4] Inst Municipal Invest Med, E-08003 Barcelona, Spain
[5] Inst Psychiat, Personal Social Services Res Unit, London Sch Econ, Ctr Econ Mental Hlth, London, England
关键词
antipsychotic agents; epidemiologic research design; Europe; longitudinal studies; multicentre studies; schizophrenia; treatment outcome;
D O I
10.1034/j.1600-0447.2003.00064.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The objective of the European Schizophrenia Outpatient Health Outcomes (SOHO) study is to understand the comparative costs and outcomes of antipsychotic drug treatment, with specific focus on olanzapine. The study will also provide a large database for research into the treatment and outcome of schizophrenia. The role of observational studies in the assessment of the effectiveness of antipsychotic agents is reviewed, and the rationale, design and recruitment issues surrounding the SOHO study are presented. Method: SOHO is a 3-year, prospective, observational study of the health outcomes associated with antipsychotic treatment in Europe. Results: Over 10 000 patients have been recruited from 10 countries. Baseline evaluation included measures of clinical status, social functioning, quality of life, service use and pharmacological treatment. Patients will be followed for 3 years. Conclusion: The SOHO study will complement randomized controlled trial findings on the treatment of schizophrenia and will address relevant clinical and policy research questions.
引用
收藏
页码:222 / 232
页数:11
相关论文
共 81 条
[31]   The safety of olanzapine compared with other antipsychotic drugs:: Results of an observational prospective study in patients with schizophrenia (EFESO study) [J].
Gómez, JC ;
Sacristán, JA ;
Hernández, J ;
Breier, A ;
Carrasco, PR ;
Saiz, CA ;
Carbonell, EF .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (05) :335-343
[32]  
Guy W., 1976, Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, DHEW Publ No ADM 76-338, pp 218-222., P218
[33]  
HALEY JC, 1998, VALUE HEALTH, V1, P89
[34]   Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample [J].
Hamilton, SH ;
Edgell, ET ;
Revicki, DA ;
Breier, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 (05) :245-255
[35]   Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia - Results from a randomised clinical trial [J].
Hamilton, SH ;
Revicki, DA ;
Edgell, ET ;
Genduso, LA ;
Genduso, LA ;
Tollefson, G .
PHARMACOECONOMICS, 1999, 15 (05) :469-480
[36]   Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain [J].
Haro, JM ;
Salvador-Carulla, L ;
Cabasés, J ;
Madoz, V ;
Vázquez-Barquero, JL .
BRITISH JOURNAL OF PSYCHIATRY, 1998, 173 :334-340
[37]   Excess mortality of mental disorder [J].
Harris, EC ;
Barraclough, B .
BRITISH JOURNAL OF PSYCHIATRY, 1998, 173 :11-53
[38]  
HECKMAN JJ, 1992, EVALUATING WELFARE AND TRAINING PROGRAMS, P201
[39]   A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia [J].
Ho, BC ;
Miller, D ;
Nopoulos, P ;
Andreasen, NC .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (10) :658-663
[40]   Selection bias in clinical trials with antipsychotics [J].
Hofer, A ;
Hummer, M ;
Huber, R ;
Kurz, M ;
Walch, T ;
Fleischhacker, WW .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (06) :699-702